The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about ...

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...

SOMERVILLE, Mass., April 16, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird" or "the Company") today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd.

Bluebird Bio (BLUE) announced that after three weeks of engagement, including a timeline extension, Ayrmid has not submitted a binding proposal ...

(RTTNews) - Bluebird bio, Inc. (BLUE), the Massachusetts based biotechnology company, on Wednesday announced that after three weeks of discussions and an extended deadline Ayrmid Ltd. has not made ...

--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd ...

“Ayrmid’s proposal remains highly conditional, despite an extension to the previously agreed-upon timeline to complete confirmatory diligence and submit a binding offer,” said Mark ...

Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right ...

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track ...